All News

Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.

The financial burden of in vitro fertilization (IVF) medications has become increasingly prohibitive, limiting the availability of fertility treatments for many.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

Drug Topics sat down with Adam J. James, PharmD, to discuss learnings from his extensive experience at Rite Aid.

In a systematic review, researchers explored the role of clinical pharmacists within a multidisciplinary team treating patients with inflammatory bowel disease.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

David Pope, PharmD, Chief Pharmacy Officer at XiFin, shared his thoughts on value-based care and how it is used within a pharmacy setting.

As health care systems and the current syndemic continue to evolve, pharmacies are poised to play a crucial role in improving public health.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

Jon Minkin, enterprise account executive at NimbleRx, shared how his company can help independent pharmacies unlock revenue opportunities.

Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.

In case you missed it, this week we had stories about medication-related disaster preparedness, COVID-19 and cardiovascular risks, legal battles over inflated insulin prices, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of October 7.

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

The partnership will provide tools to address both patient and pharmacist well-being amid the current mental health crisis.

Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.

Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.

The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Two posters presented at the annual meeting of the American College of Chest Physicians, CHEST 2024, offered insights into the accurate diagnosis and appropriate treatment of ACOS.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

Emily Endres, BSPS, vice president of pharmacy at PQS by Innovaccer, provides insights into the industry’s next phase.

On October 3,2024, Texas Attorney General Ken Paxton issued the lawsuit, which involves Eli Lilly, Express Scripts, CVS Pharmacy, and other pharmaceutical entities.